STVN Stock Analysis: Stevanato | NYSE

Pre-Fillable Syringes, Glass Containers, Injection Devices, Inspection Machines

Total Rating 48

Safety 85

Buy Signal -0.71

Medical Instruments & Supplies
Industry Rotation: +10.5

Market Cap: 5.79B
Avg Turnover: 9.20M

Risk 3d forecast

Volatility49.2%

VaR 5^th Pctl8.54%

VaR vs Median5.35%

Reward TTM

Sharpe Ratio0.12

Rel. Str. IBD67.4

Rel. Str. Peer Group56.3

Character TTM

Beta0.381

Beta Downside0.056

Hurst Exponent0.596

Drawdowns 3y

Max DD61.03%

CAGR/Max DD-0.19

CAGR/Mean DD-0.34

EPS (Earnings per Share)

EPS CAGR: 3.37%
EPS Trend: 33.9%

Last SUE: 0.64
Qual. Beats: 0

Revenue

Rev. CAGR: 5.22%
Rev. Trend: 97.8%

Last SUE: 0.21
Qual. Beats: 0

Warnings

Fakeout

Tailwinds

No distinct edge detected

Seasonality 5 years of data

Jan +6.2% 24

Feb +0.6% 0

Mar +2.6% 0

Apr -0.1% 0

May +0.8% 0

Jun +2.0% 0

Jul +8.7% 12

Aug -0.3% 0

Sep -0.0% 0

Oct -3.5% 22

Nov -7.4% 29

Dec +4.5% 21

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: STVN Stevanato

Stevanato Group S.p.A. (NYSE: STVN) is an Italy-based provider of drug containment, drug delivery, and diagnostic solutions serving the biopharma and healthcare industries worldwide. Founded in 1949 and headquartered in Piombino Dese, Italy, the company operates through two segments-Biopharmaceutical and Diagnostic Solutions, and Engineering-and is a subsidiary of Stevanato Holding S.R.L.

Its product portfolio spans primary glass packaging (pre-fillable syringes, cartridges, vials, and ampoules), drug delivery devices (pen injectors, auto-injectors, and wearable injectors), in-vitro diagnostic consumables, and pharmaceutical manufacturing equipment such as visual inspection machines, assembling and packaging machines, and glass converting machines. The company also provides analytical and regulatory support, after-sales services, and contract development and manufacturing for customer-owned drug delivery devices.

Stevanatos customer base includes pharmaceutical, biotechnology, diagnostics, and life sciences companies, as well as contract manufacturers involved in fill and finish operations. The company operates on a global footprint, with commercial reach across Europe, the Middle East, Africa, North America, South America, and the Asia Pacific, and has been listed on the NYSE since its IPO in July 2021.

As a supplier of glass primary packaging and integrated device solutions, Stevanato sits within a specialized B2B niche of the healthcare equipment value chain, where customers are highly regulated drug manufacturers with long product life cycles. The company competes in a relatively consolidated market for high-quality tubular glass and pre-sterilized containers, an area where demand is closely tied to trends in biologics, biosimilars, injectable therapies, and self-administration drug delivery formats.

Headlines to Watch Out For

GLP-1 demand surge drives pre-fillable syringe order growth
Engineering segment revenue expands on pharmaceutical equipment capex
Schott and Gerresheimer competition pressures drug containment pricing margins

Piotroski VR-10 (Strict) 7.0

Net Income: 134.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.01 > 0.02 and ΔFCF/TA 5.09 > 1.0
NWC/Revenue: 29.01% < 20% (prev 33.11%; Δ -4.10% < -1%)
CFO/TA 0.09 > 3% & CFO 247.0m > Net Income 134.2m
Net Debt (370.8m) to EBITDA (291.7m): 1.27 < 3
Current Ratio: 1.61 > 1.5 & < 3
Outstanding Shares: last quarter (273.0m) vs 12m ago 0.03% < -2%
Gross Margin: 29.16% > 18% (prev 28.04%; Δ 1.12% > 0.5%)
Asset Turnover: 49.17% > 50% (prev 48.70%; Δ 0.47% > 0%)
Interest Coverage Ratio: 20.69 > 6 (EBIT TTM 196.5m / Interest Expense TTM 9.50m)

Altman Z'' 4.22

A: 0.14 (Total Current Assets 932.7m - Total Current Liabilities 578.3m) / Total Assets 2.62b
B: 0.39 (Retained Earnings 1.03b / Total Assets 2.62b)
C: 0.08 (EBIT TTM 196.5m / Avg Total Assets 2.49b)
D: 1.45 (Book Value of Equity 1.55b / Total Liabilities 1.07b)
Altman-Z'' = 4.22 = AA

Beneish M -3.03

DSRI: 1.05 (Receivables 539.7m/480.8m, Revenue 1.22b/1.15b)
GMI: 0.96 (GM 28.04% / 29.16%)
AQI: 0.91 (AQ_t 0.08 / AQ_t-1 0.08)
SGI: 1.07 (Revenue 1.22b / 1.15b)
TATA: -0.04 (NI 134.2m - CFO 247.0m) / TA 2.62b)
Beneish M = -3.03 (Cap -4..+1) = AA

What is the price of STVN shares?

As of August 26, 2026, the stock is trading at USD 22.27 with a total of 1,309,683 shares traded. Over the past week, the price has changed by +4.75%, over one month by +13.16%, over three months by +24.38% and over the past year by +1.64%.

Current recommended Stop Loss: 21.20 (which is 4.8% or 1.4 ATR below the current price).

Is STVN a buy, sell or hold?

Stevanato has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy STVN.

StrongBuy: 6
Buy: 2
Hold: 3
Sell: 0
StrongSell: 0

What are the forecasts/targets for the STVN price?

Analysts Target Price	24.7	11.1%

Stevanato (STVN) - Fundamental Data Overview as of 20 August 2026

Market Cap USD = 5.79b (5.79b USD * 1.0 USD.USD)
Market Cap EUR = 4.95b (5.79b USD * 0.8557 USD.EUR)
P/E Trailing = 37.193
P/E Forward = 6.8587
P/S = 4.7259
P/B = 3.2389
P/EG = 0.3671
Revenue TTM = 1.22b EUR
EBIT TTM = 196.5m EUR
EBITDA TTM = 291.7m EUR
Long Term Debt = 312.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 123.9m EUR (from shortTermDebt, last quarter)
Debt = 454.3m EUR (from shortLongTermDebtTotal, last quarter) + Leases 11.3m
Net Debt = 370.8m EUR (calculated: Debt 454.3m - CCE 83.6m)
Enterprise Value = 5.32b EUR (4.95b + Debt 454.3m - CCE 83.6m)
Interest Coverage Ratio = 20.69 (Ebit TTM 196.5m / Interest Expense TTM 9.50m)
EV/FCF = -207.8x (Enterprise Value 5.32b / FCF TTM -25.6m)
FCF Yield = -0.48% (FCF TTM -25.6m / Enterprise Value 5.32b)
FCF Margin = -2.10% (FCF TTM -25.6m / Revenue TTM 1.22b)
Net Margin = 10.99% (Net Income TTM 134.2m / Revenue TTM 1.22b)
Gross Margin = 29.16% ((Revenue TTM 1.22b - Cost of Revenue TTM 865.6m) / Revenue TTM)
Gross Margin QoQ = 28.74% (prev 27.48%)
Tobins Q-Ratio = 2.03 (Enterprise Value 5.32b / Total Assets 2.62b)
Interest Expense / Debt = 2.09% (Interest Expense 9.50m / Debt 454.3m)
Taxrate = 29.95% (57.4m / 191.6m)
NOPAT = 137.7m (EBIT 196.5m * (1 - 29.95%))
Current Ratio = 1.61 (Total Current Assets 932.7m / Total Current Liabilities 578.3m)
Debt / Equity = 0.29 (Debt 454.3m / totalStockholderEquity, last quarter 1.55b)
Debt / EBITDA = 1.27 (Net Debt 370.8m / EBITDA 291.7m)
Debt / FCF = -14.47 (negative FCF - burning cash) (Net Debt 370.8m / FCF TTM -25.6m)
Total Stockholder Equity = 1.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.40% (Net Income 134.2m / Total Assets 2.62b)
RoE = 8.94% (Net Income TTM 134.2m / Total Stockholder Equity 1.50b)
RoCE = 10.84% (EBIT 196.5m / Capital Employed (Equity 1.50b + L.T.Debt 312.0m))
RoIC = 6.55% (NOPAT 137.7m / Invested Capital 2.10b)
WACC = 6.83% (E(4.95b)/V(5.41b) * Re(7.32%) + D(454.3m)/V(5.41b) * Rd(2.09%) * (1-Tc(0.30)))
Discount Rate = 7.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 54.73 | Cagr: 1.16%
[DCF] Fair Price = unknown (Cash Flow -25.6m)
EPS Correlation: 33.92 | EPS CAGR: 3.37% | SUE: 0.64 | # QB: 0
Revenue Correlation: 97.85 | Revenue CAGR: 5.22% | SUE: 0.21 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.18 | Chg30d=-2.73% | Revisions=-73% | Analysts=10
EPS current Year (2026-12-31): EPS=0.70 | Chg30d=+0.26% | Revisions=-42% | GrowthEPS=+12.4% | GrowthRev=+7.1%
EPS next Year (2027-12-31): EPS=0.84 | Chg30d=+0.52% | Revisions=-21% | GrowthEPS=+19.3% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: -52% (up=6, down=22)